JP2009533356A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533356A5
JP2009533356A5 JP2009504530A JP2009504530A JP2009533356A5 JP 2009533356 A5 JP2009533356 A5 JP 2009533356A5 JP 2009504530 A JP2009504530 A JP 2009504530A JP 2009504530 A JP2009504530 A JP 2009504530A JP 2009533356 A5 JP2009533356 A5 JP 2009533356A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
use according
derivative
acceptable salt
list
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009504530A
Other languages
English (en)
Japanese (ja)
Other versions
JP5290147B2 (ja
JP2009533356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/000490 external-priority patent/WO2007118276A1/en
Publication of JP2009533356A publication Critical patent/JP2009533356A/ja
Publication of JP2009533356A5 publication Critical patent/JP2009533356A5/ja
Application granted granted Critical
Publication of JP5290147B2 publication Critical patent/JP5290147B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009504530A 2006-04-14 2007-04-13 加齢黄斑変性症(amd)の処置方法 Expired - Fee Related JP5290147B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79227806P 2006-04-14 2006-04-14
US60/792,278 2006-04-14
PCT/AU2007/000490 WO2007118276A1 (en) 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration(amd)

Publications (3)

Publication Number Publication Date
JP2009533356A JP2009533356A (ja) 2009-09-17
JP2009533356A5 true JP2009533356A5 (enExample) 2011-04-21
JP5290147B2 JP5290147B2 (ja) 2013-09-18

Family

ID=38608967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009504530A Expired - Fee Related JP5290147B2 (ja) 2006-04-14 2007-04-13 加齢黄斑変性症(amd)の処置方法

Country Status (14)

Country Link
US (3) US20100144693A1 (enExample)
EP (2) EP2012789B1 (enExample)
JP (1) JP5290147B2 (enExample)
KR (2) KR20100110396A (enExample)
CN (3) CN101534826A (enExample)
AU (2) AU2007240120A1 (enExample)
BR (2) BRPI0722382A2 (enExample)
CA (1) CA2683756A1 (enExample)
DK (1) DK2012789T3 (enExample)
ES (1) ES2437997T3 (enExample)
IL (1) IL207495A (enExample)
NZ (2) NZ572591A (enExample)
WO (1) WO2007118276A1 (enExample)
ZA (2) ZA200809493B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
EP2044026B1 (en) * 2006-06-22 2014-03-26 Prana Biotechnology Limited Method of treatment of glioma brain tumour
EP2331525A4 (en) * 2008-08-11 2013-01-02 Harvard College HALOFUGINONE ANALOGUE FOR INHIBITING TRNA SYNTHETASES AND APPLICATIONS THEREOF
DK2379510T3 (en) * 2008-12-24 2016-12-19 Prana Biotechnology Ltd quinazolinone
EA201170970A1 (ru) 2009-01-26 2012-03-30 Майкл Спино Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
EP2802572B1 (en) 2012-01-13 2018-11-07 President and Fellows of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
HK1217325A1 (zh) 2012-12-20 2017-01-06 奥尔德拉医疗公司 迫位原醇
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
CA2898869A1 (en) 2013-01-25 2014-07-31 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
AU2015358284B2 (en) * 2014-12-02 2020-07-02 Prana Biotechnology Limited 4H-pyrido[1,2-a]pyrimidin-4-one compounds
EP3290969B1 (en) * 2015-04-29 2021-06-23 Triapex Co., Ltd. Polarizing lens including a polarizing film
US10781178B2 (en) * 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2017053696A2 (en) * 2015-09-24 2017-03-30 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents
WO2017196881A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
JP7025358B2 (ja) * 2016-07-01 2022-02-24 オールテリティ セラピューティクス リミテッド 免疫グロブリン軽鎖アミロイドーシスを治療する方法
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
CN109232396B (zh) * 2018-11-27 2020-07-03 聊城大学 酰胺吡啶类衍生物及其用途
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス, インコーポレイテッド 多形化合物およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
JP2023532134A (ja) * 2020-07-02 2023-07-26 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 網膜変性の処置において使用するための環式化合物
US12060334B2 (en) 2021-03-12 2024-08-13 University Of Florida Research Foundation, Incorporated 3-substituted phenazine derivatives as antimicrobial agents
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE505711A (enExample) 1950-09-09
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
HU178910B (en) * 1977-08-19 1982-07-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
KR100304200B1 (ko) 1993-04-08 2001-11-22 에카르트 마이너스 클라우스 제이 륄러 위생수도꼭지
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
NZ334124A (en) * 1996-08-13 2000-10-27 P Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
CN1263733C (zh) 1998-10-22 2006-07-12 神经研究公司 取代苯基衍生物,它们的制备和用途
US6369058B1 (en) * 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
AU7080500A (en) 1999-08-27 2001-03-26 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
FR2819187A1 (fr) * 2001-01-10 2002-07-12 Michel Xilinas Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
CA2456155A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
CA2500952C (en) * 2002-10-04 2011-04-26 Prana Biotechnology Limited Neurologically-active compounds
CN1791408A (zh) * 2003-04-03 2006-06-21 普拉纳生物技术有限公司 神经系统疾病的治疗
CA2529256A1 (en) * 2003-06-23 2004-12-29 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
MXPA06011236A (es) * 2004-04-02 2007-01-16 Prana Biotechnology Ltd Compuestos neurologicamente activos.
CA2593846A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
EP2044026B1 (en) * 2006-06-22 2014-03-26 Prana Biotechnology Limited Method of treatment of glioma brain tumour

Similar Documents

Publication Publication Date Title
JP2009533356A5 (enExample)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
JP2010518122A5 (enExample)
JP2015505564A5 (enExample)
JP2012184234A5 (enExample)
WO2009063202A3 (en) Use of crth2 antagonist compounds
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
JP2015523546A5 (enExample)
JP2023116697A5 (enExample)
JP2014505107A5 (enExample)
JP2015522018A5 (enExample)
JP2014513065A5 (enExample)
JP2017105859A5 (enExample)
JP2014508758A5 (enExample)
JP2008534503A5 (enExample)
JP2008540528A5 (enExample)
JP2007530703A5 (enExample)
JP2018525447A5 (enExample)
UA122336C2 (uk) Бісамідна похідна дикарбонової кислоти як засіб, що стимулює регенерацію тканин і відновлення знижених функцій тканин
JP2006510659A5 (enExample)
JP2008543853A5 (enExample)
JP2002522462A5 (enExample)
JP2013502449A5 (enExample)